DRG Market Assessment reports

Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…

Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…

The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…

HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…

Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…

China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…